top of page
  • Recruiting

NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM

Updated: Jun 13, 2022

Multiple Myeloma Research Consortium

phase 2 study

Dara-KRd

Multiple Myeloma Research Consortium

NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma



Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma


The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.


Sponsor:

University of Chicago


Collaborators:

Janssen Scientific Affairs, LLC

Amgen